On the 25th of September, Orbimed Capital purchased 1.2 million Prelude Therapeutics Incorporat (PRLD) shares for $23 million at an average price of $19.00 per share. Shares of Prelude Therapeutics Incorporat are up 57.52% since the transaction.
Orbimed Capital's holding in Prelude Therapeutics Incorporat established a new holding of about 917 thousand shares with the purchase.